United States · FDA National Drug Code directory
Darifenacin
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 65862-861_389b20f0-64d5-46f6-bb3b-74feb1a9898b
- Product NDC
- 65862-861
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Composition / generic term
- Darifenacin
- Labeler
- Aurobindo Pharma Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20160919
- Source listing expiry
- 20261231
Source-listed ingredients
- DARIFENACIN HYDROBROMIDE — 7.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-861-05) · 65862-861-05
- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-861-30) · 65862-861-30
- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-861-90) · 65862-861-90
- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-861-99) · 65862-861-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →